Biogen shoves Aduhelm to the side. It's time for lecanemab

But where does that leave Biogen and partner Eisai? Well, lecanemab is heading to regulators at full speed, with some hard lessons learned from the Aduhelm fallout that the companies will leverage in an attempt to do better. Eisai will lead the regulatory process this time and is in charge of the regulatory filing, whereas Biogen handled that aspect for Aduhelm.